PMID: 7018679Jul 1, 1981Paper

Efficacy of piperazinedione prior to bone marrow transplantation: studies in a rat model for human acute myelocytic leukemia

Cancer Treatment Reports
A Hagenbeek, A C Martens

Abstract

The efficacy and toxicity of piperazinedione were investigated in a Brown Norway rat model for acute myelocytic leukemia (BNML). Treatment was started at a stage which is comparable to a "full-blown" relapse in human patients. Early toxicity-induced deaths due to the very strong myelosuppressive effect of the drug could be prevented by bone marrow transplantation followed by repeated blood transfusions. However, with a total dose of 16 mg/kg (human dose, 85 mg/m2), death caused by GI tract and lung damage was inevitable. As judged by prolongation of survival, at the most of a 9-log cell-kill was achieved. No cures were obtained, since the total tumor load at the start of treatment was greater than 10(9) cells (about 5 X 10(9)). The possible presence of drug-resistant cells was not excluded. No significant differences in efficacy were found between daily "push" treatment and split daily doses using total doses of 10-12 mg/kg.

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.